Abrignani Sergio

Chief Scientific Officer

Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
Bosè F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, Caprioli F, Scavelli R, Altomare G, Geginat J, Abrignani S, Reali E.
Clin Immunol. 2011 May;139(2):164-76.

Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.
Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, Houghton M, Frey SE, Belshe RB.
J Infect Dis. 2010 Sep 15;202(6):862-6.

Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.
Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB.
Vaccine. 2010 Aug 31;28(38):6367-73.

CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function.
Rivino L, Gruarin P, Häringer B, Steinfelder S, Lozza L, Steckel B, Weick A, Sugliano E, Jarrossay D, Kühl AA, Loddenkemper C, Abrignani S, Sallusto F, Lanzavecchia A, Geginat J.
J Exp Med. 2010 Mar 15;207(3):565-77.

B cell helper assays.
Abrignani S, Tonti E, Casorati G, Dellabona P.
Methods Mol Biol. 2009;514:15-26.

NKT-cell help to B lymphocytes can occur independently of cognate interaction.
Tonti E, Galli G, Malzone C, Abrignani S, Casorati G, Dellabona P.
Blood. 2009 Jan 8;113(2):370-6.

Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function.
Serra A, Nuti S, Tavarini S, Sammicheli C, Rosa D, Saletti G, Soldaini E, Abrignani S, Wack A.
J Immunol. 2008 Jul 1;181(1):174-85.

Prophylaxis of hepatitis C with intramuscular immunoglobulin: clinical and economic appraisal.
Piazza M, Sagliocca L, Tosone G, Guadagnino V, Stazi MA, Orlando R, Borgia G, Rosa D, Abrignani S, Palumbo F, Manzin A, Clementi M.
BioDrugs. 1999 Oct;12(4):291-300.

Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.
Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, Fong YL, Chien D, Abrignani S, Balfe P, Rice CM, McKeating JA, Houghton M.
Vaccine. 2007 Nov 7;25(45):7773-84.

Invariant NKT cells sustain specific B cell responses and memory.
Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, Maione D, Volpini G, Finco O, Nuti S, Tavarini S, Dellabona P, Rappuoli R, Casorati G, Abrignani S.
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3984-9.

Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line.
Brazzoli M, Crotta S, Bianchi A, Bagnoli F, Monaghan P, Wileman T, Abrignani S, Merola M.
J Hepatol. 2007 Jan;46(1):53-9.

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses.
Vajdy M, Selby M, Medina-Selby A, Coit D, Hall J, Tandeske L, Chien D, Hu C, Rosa D, Singh M, Kazzaz J, Nguyen S, Coates S, Ng P, Abrignani S, Lin YL, Houghton M, O’Hagan DT.
J Gen Virol. 2006 Aug;87(Pt 8):2253-62.

Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells.
Crotta S, Ronconi V, Ulivieri C, Baldari CT, Valiante NM, Abrignani S, Wack A.
Eur J Immunol. 2006 Apr;36(4):919-29. Erratum in: Eur J Immunol. 2006 May;36(5):1350. Valiente, Nicholas M [corrected to Valiante, Nicholas M].

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.
Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D’Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G, Abrignani S.
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9.

Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.
Kong WP, Xu L, Stadler K, Ulmer JB, Abrignani S, Rappuoli R, Nabel GJ.
J Virol. 2005 Nov;79(22):13915-23

INGM researches are supported by